Polymorph Form I dCK Inhibitor Maleate Salt
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with deoxycytidine kinase (dCK) activity, such as cancer and autoimmune diseases, lack effective inhibitors that can specifically target dCK.
Innovation Solution
A crystalline form of a compound of Formula I, specifically a polymorph Form I of a maleate salt, is developed, characterized by unique differential scanning calorimetry, X-ray powder diffraction, and thermogravimetric analysis profiles, which serves as a potent and selective dCK inhibitor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for diseases associated with dCK activity, then treatment is provided, but effective and specific dCK inhibition is not achieved
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of compounds to optimize their binding affinity and selectivity for dCK. Specifically, the compound of Formula I and its polymorph Form I represent a specific chemical parameter configuration that achieves potent and selective dCK inhibition, distinguishing it from previous treatments that lacked this level of specificity and efficacy.
2Reliability
If a crystalline form of compound is developed, then potency and selectivity are improved, but manufacturing complexity increases
Solution Approach 1:
The patent utilizes phase transitions by specifically developing and characterizing polymorph Form I of the maleate salt of the compound. This crystalline phase exhibits enhanced potency and selectivity compared to other forms. The patent provides detailed characterization data including X-ray powder diffraction patterns, differential scanning calorimetry thermograms, and thermogravimetric analysis profiles to define this specific phase, enabling consistent manufacturing through controlled crystallization processes.
Data Source
AI summary
Described herein are crystalline forms of compounds that are deoxycytidine kinase (dCK) inhibitors, methods of making such crystalline forms, pharmaceutical compositions and medicaments comprising such crystalline forms, and methods of using such crystalline forms in the treatment of conditions, diseases, or disorders that would benefit from modulation of deoxycytidine kinase (dCK) activity.